Enter the clinic with auremolimab, an anti-IL-15Rβ monoclonal antibody
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Aug 2023
- Due
- 31 Dec 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Auremolimab, an anti-IL-15Rβ monoclonal antibody, received IND clearance and is expected to enter the clinic later this year.”
What we found
Evidence strength A What the grades mean
Later 10-K filings state the anti-IL-15Rβ antibody INCA034460 received IND clearance in July 2023 and a first patient was dosed in October 2023, before the year-end deadline.
-
A Incyte 10-K filed 2024-02-13
“In July 2023, INCA034460 received Investigational New Drug application (IND) clearance and in October 2023, we announced the first patient had been dosed.” ✓ confirmed on the page
-
A Incyte 10-K filed 2025-02-10
“INCA034460 is a novel, humanized anti-IL-15Rβ monoclonal antibody designed to target and deplete autoreactive tissue resident memory T cells (TRM)” ✓ confirmed on the page
Market reaction: the shares moved +1.8% against the S&P 500 over the three sessions around the disclosure (12 Feb 2024 to 15 Feb 2024). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Project other
- Indicative materiality
- Low rules
- Action
- Enter
- Deliverable
- Auremolimab clinical entry
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-INCY-005714 · Corrections policy